Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–4 of 4 results
Advanced filters: Author: Matthias Drosten Clear advanced filters

  • The established role of theRETproto-oncogene in the development of medullary thyroid carcinoma makes this gene an attractive target for selective cancer therapy. The current evidence of RET involvement in the etiology of medullary thyroid carcinoma, and the therapeutic targeting of this process in preclinical and clinical studies are discussed, and the authors propose why targeting the RET proto-oncogene with small-molecule drugs is very likely to be successful in clinical applications.

    • Matthias Drosten
    • Brigitte M Pützer
    Reviews
    Nature Clinical Practice Oncology
    Volume: 3, P: 564-574

  • The success of targeting KRAS for cancer therapy is limited by resistance due to compensatory mechanism, making combinatorial approaches attractive. Here, the authors use a KRAS signature drug repurposing screen and identify the multityrosine kinase PKC inhibitor Midostaurin as synergistic with MEK and KRAS inhibitors in KRAS-mutated lung adenocarcinoma.

    • Irati Macaya
    • Marta Roman
    • Silve Vicent
    ResearchOpen Access
    Nature Communications
    Volume: 14, P: 1-19

  • Hypoactive BRAF mutants bind more tightly than wild type to the upstream regulator RAS, thus amplifying to amplify ERK signalling; tumours expressing these mutants require coexistent mechanisms for RAS activation to grow and are sensitive to their inhibition.

    • Zhan Yao
    • Rona Yaeger
    • Neal Rosen
    Research
    Nature
    Volume: 548, P: 234-238